Selection Bias Risk in Randomized Controlled Trials Rated as Low Bias Using Risk of Bias, Version 2 (RoB2) Tool.

Our study aimed to establish the risk of selection bias in randomized controlled trials (RCT) that were overall rated as having "low bias" risk according to Cochrane's Risk of Bias, version 2 (RoB 2) tool. A systematic literature search of current systematic reviews of RCTs was conducted. From the identified reviews, RCTs with overall "high bias" and "low bias" RoB 2 risk ratings were extracted. All RCTs were statistically tested for selection bias risk. From the test results, true positive, true negative, false positive, or false negative ratings were established, and the false omission rate (FOR) with a 95% confidence interval (CI) was computed. Subgroup analysis was conducted by computing the negative likelihood ratio (-LR) concerning RoB 2 domain 1 ratings: bias arising from the randomization process. A total of 1070 published RCTs (median publication year: 2018; interquartile range: 2013-2020) were identified and tested. We found that 7.61% of all "low bias" (RoB 2)-rated RCTs were of high selection bias risk (FOR 7.61%; 95% CI: 6.31%-9.14%) and that the likelihood for high selection bias risk in "low bias" (RoB 2 domain 1)-rated RCTs was 6% higher than that for low selection bias risk (-LR: 1.06; 95% CI: 0.98-1.15). These findings raise issues about the validity of "low bias" risk ratings using Cochrane's RoB 2 tool as well as about the validity of some of the results from recently published RCTs. Our results also suggest that the likelihood of a "low bias" risk-rated body of clinical evidence being actually bias-free is low, and that generalization based on a limited, pre-specified set of appraisal criteria may not justify a high level of confidence that such evidence reflects the true treatment effect.